Monday, November 11, 2019
- 9:00AM-11:00AM
-
Abstract Number: 1520
Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1506
Long‑Term Certolizumab Pegol Treatment of Axial Spondyloarthritis Is Associated with Rapid and Sustained Reduction of Active Inflammation and Minimal Structural Changes in the Spine: 4‑Year MRI Results
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 1363
Longitudinal Work Transitions in Early Inflammatory Arthritis Patients: Are There Targets for Intervention to Improve Employment?
RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures- 9:00AM-11:00AM
-
Abstract Number: 1131
Loss to Follow-up in Registries of Rheumatic Patients Treated with Biologics: A Potentially Valuable Hidden Real-world Data That Is Being Overlooked?
Health Services Research Poster II – ACR/ARP- 9:00AM-11:00AM
-
Abstract Number: 1734
Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients
Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma- 9:00AM-11:00AM
-
Abstract Number: 1387
Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab
RA – Treatments Poster II: Established Treatments- 9:00AM-11:00AM
-
Abstract Number: 1152
Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy
Healthcare Disparities In Rheumatology Poster- 9:00AM-11:00AM
-
Abstract Number: 1628
Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom
Systemic Sclerosis & Related Disorders – Clinical Poster II- 9:00AM-11:00AM
-
Abstract Number: 1028
Lupus Auto-antibodies Act as Positive Allosteric Modulators at GluN2A-containing NMDA Receptors to Induce Excitotoxicity and Spatial Memory Deficits
SLE – Etiology & Pathogenesis Poster I- 9:00AM-11:00AM
-
Abstract Number: 1111
Lupus Teledematology: A Pilot Project to Evaluate the Plausibility of a Rapid Access Dermatology Service for Lupus Patients
Health Services Research Poster II – ACR/ARP- 9:00AM-11:00AM
-
Abstract Number: 1062
Lymphocyte Subset Abnormalities in Early Diffuse Cutaneous Systemic Sclerosis
Systemic Sclerosis & Related Disorders – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 1575
Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change
SLE – Clinical Poster II: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 1024
Lysosome Defects in SLE Promote the Accumulation of Nuclear Antigens on the Surface of Hematopoietic Cells
SLE – Etiology & Pathogenesis Poster I